Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Flagstar Bank NA (FLG) vs Mesoblast Limited (MESO) Price & Performance

Flagstar Bank NATrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Flagstar Bank NA vs Mesoblast Limited — how do they compare? Flagstar Bank NA trades at $11.36 (market cap $4.71B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Flagstar Bank NA is far larger — about 2.7× Mesoblast Limited's market cap, and Flagstar Bank NA pays a 0.35% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 21 Days and Mesoblast Limited for 14 Days on average.

FLGMESO
Market Cap
$4.71B$1.75B
Volume
7,410,589239,027
Sector
FinancialsHealth
52-Week High
$15.36$20.96
52-Week Low
$10.72$13.19
Typical Hold Time
21 Days14 Days
Enterprise Value
$15.25B$1.83B
Dividend Yield
0.35%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Flagstar Bank NA

Flagstar Bank (FLG) trades at $11.30, down 2.25% on the day, with a bearish technical outlook despite recent earnings beats. The company shows improving fundamentals with Q2 2026 marking the third consecutive profitable quarter, though it missed EPS estimates. Analyst sentiment remains positive with a $17.07 consensus price target representing 51% upside potential. Recent strategic developments include a $250 million share repurchase program and a new core banking partnership with Fiserv.

The stock presents a compelling value opportunity trading at 0.62x book value, but faces risks from volatile earnings performance and negative cash flow trends. While analyst consensus is bullish with 60% buy ratings, investors should monitor execution on profitability improvements and the impact of recent strategic initiatives on long-term growth.

Mesoblast Limited

MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.

While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Flagstar Bank NA

Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.

Read more on FLG →

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO →